Stockwatch: Limited Acquisition Headroom At Specialty Pharma

 
• By Andy Smith

Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.

Stockwatch_1200x675
Andy Smith gives a life sciences investor's perspective on biopharma business

More from Deals

More from Business